著者: TaylorJerome H, JakubovskiEwgeni, GabrielDaniel, BlochMichael H

原題: Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study.

著者: KrauseMarc, ZhuYikang, HuhnMaximilian, Schneider-ThomaJohannes, BighelliIrene, ChaimaniAnna, LeuchtStefan

原題: Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis.

著者: ZhuYikang, KrauseMarc, HuhnMaximilian, RothePhilipp, Schneider-ThomaJohannes, ChaimaniAnna, LiChunbo, DavisJohn M, LeuchtStefan

原題: Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses.

著者: FindlingRobert L, JohnsonJacqueline L, McClellanJon, FrazierJean A, VitielloBenedetto, HamerRobert M, LiebermanJeffrey A, RitzLouise, McNamaraNora K, LinglerJacqui, HlastalaStefanie, PiersonLeslie, PugliaMadeline, MaloneyAnn E, KaufmanEmily Michael, NoyesNancy, SikichLinmarie

原題: Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.

著者: AparasuRajender R, JanoElda, JohnsonMichael L, ChenHua

原題: Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients.

著者: BaptistaT, KinN M K N Y, BeaulieuS, de BaptistaE A

原題: Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.

著者: PinkofskyH B

原題: Psychosis during pregnancy: treatment considerations.

著者: ZengX P, LeF, RichelsonE

原題: Muscarinic m4 receptor activation by some atypical antipsychotic drugs.

著者: PijlH, MeindersA E

原題: Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.

著者: FernandezF, LevyJ K

原題: The use of molindone in the treatment of psychotic and delirious patients infected with the human immunodeficiency virus. Case reports.

著者: NeeperR, RichelsonE, NelsonA

原題: Neuroleptic binding to muscarinic M2 receptors of normal human heart in vitro and comparison with binding to M1 and dopamine D2 receptors of brain.

著者: AnguloJ A, CadetJ L, WoolleyC S, SuberF, McEwenB S

原題: Effect of chronic typical and atypical neuroleptic treatment on proenkephalin mRNA levels in the striatum and nucleus accumbens of the rat.

著者: AnguloJ A, CadetJ L, McEwenB S

原題: Effect of typical and atypical neuroleptic treatment on protachykinin mRNA levels in the striatum of the rat.

著者: PandurangiA K, NarasimhachariN, BlackardW G, LandaB S

原題: Relation of serum molindone levels to serum prolactin levels and antipsychotic response.

著者: OwenR R, ColeJ O

原題: Molindone hydrochloride: a review of laboratory and clinical findings.

著者: MooreN C, GershonS

原題: Which atypical antipsychotics are identified by screening tests?

著者: JavittD C, WeinsteinS L, OplerL A

原題: The possible role of dopamine autoreceptors in neuroleptic atypicality.

著者: MarkowitzJ C, BrownR P

原題: Seizures with neuroleptics and antidepressants.

著者: EllenbroekB A, PeetersB W, HonigW M, CoolsA R

原題: The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs.

著者: MunyonW H, SaloR, BrionesD F

原題: Cytotoxic effects of neuroleptic drugs.

著者: PeperM

原題: Clinical experience with molindone hydrochloride in geriatric patients.

著者: EscobarJ I, MannJ J, KellerJ, WilkinsJ, MasonB, MillsM J

原題: Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics.

著者: FryeP E, PariserS F, KimM H, O'ShaughnessyR W

原題: Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia.

著者: SmallJ G, KellamsJ J, DennisJ L, MilsteinV

原題: Comparison of molindone and tranylcypromine in the treatment of refractory depression.

著者: DewanM J, KossM

原題: The clinical impact of reported variance in potency of antipsychotic agents.

著者: RobertsonG S, MatsumuraH, FibigerH C

原題: Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity.